Poster Presentation 2025 Joint Meeting of the COSA ASM and IPOS Congress

Trial in progress: Feasibility and efficacy of a remotely-delivered nutrition and exercise support (ProHealth) program for patients with prostate cancer (126737)

Brenton Baguley 1 , Rob Daly 1 , Trish Livingston 1 , Jonathan Rawstorn 1 , Victoria White 1 , Harriet Koorts 1 , Steve Fraser 1 , Jason Gardner 1 , Lauren Atkins 1 , Belinda Steer 2 , Nicole Heneka 3 , Garrett Russell 4 , Gregory McNamara 5 , Nicole Kiss 1
  1. Deakin University, Melbourne, VICTORIA, Australia
  2. Nutrition and Speech Pathology , Peter MacCallum Cancer Centre, Melbourne, VIC, Australia
  3. Centre for Health Research, University of Southern Queensland, Springfield, QLD, Australia
  4. Consumer representative, Prostate Cancer Foundation of Australia, Brisbane, QLD, Australia
  5. Consumer representative, Prostate Cancer Foundation of Australia, Sydney, NSW, Australia

Background and rationale

Androgen deprivation therapy (ADT) improves survival in advanced prostate cancer but causes debilitating side effects, including sarcopenic obesity and a 10–45% increased risk of co-morbidities. Guidelines recommend exercise and nutrition interventions, but access is limited, and referral pathways are unclear. This study aims to design and evaluate a new remotely delivered nutrition and exercise model of care (ProHealth) to mitigate ADT-related side effects.

Methods

This 12-week randomised controlled trial (target n=50) includes patients treated with ADT, randomised (1:1) to ProHealth or usual care. ProHealth was co-designed with health professionals (n=13) and consumers (n=9) and includes (i) education on prostate cancer and side effects and (ii) multimedia behaviour change resources to support remote nutrition and exercise video consultations. The ProHealth group receives tailored nutrition therapy from a dietitian and home-based progressive resistance training (3 days/week) guided by an exercise physiologist at baseline, and weeks 1 (exercise only), 2, 4, and 8. Feasibility outcomes (reach, uptake, attendance, adherence, usage, and safety) are assessed over 12 weeks. Secondary outcomes (body composition, quality of life, fatigue, physical function, dietary intake, and physical activity) are assessed at baseline and 12 weeks. Group-by-time differences will be analysed using intention-to-treat linear mixed models.

Results

Since January 2025, 21 participants have enrolled (reach = 51; recruitment rate of eligible participants: 84%), with three completing the trial. Participants are 72 ± 5 years old, mostly overweight (BMI: 29 ± 3 kg/m²), and have been on ADT for 41 ± 44 months. Further feasibility and preliminary efficacy outcomes will be presented at the 2025 COSA Annual Scientific Meeting.

 

Conclusion and clinical implications

ProHealth is an innovative, consumer-informed, remotely delivered model with the potential to improve access to tailored, evidence-based nutrition and exercise support for patients undergoing ADT.